ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.JAMA oncology · 2026Trial
- Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma.Clinical lymphoma, myeloma & leukemia · 2020Trial
- A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.Blood · 2018Trial
- Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.Haematologica · 2018Trial
- Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas.Annals of hematology · 2025Review
- Proteomic Profiling Identifies Predictive Signatures for Progression Risk in Patients with Advanced-Stage Follicular Lymphoma.Cancers · 2024Article
- Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.Acta oncologica (Stockholm, Sweden) · 2024Article
- Follicular lymphoma: is there an optimal way to define risk?Hematology. American Society of Hematology. Education Program · 2021Review
- Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.Annals of hematology · 2020Article
- Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information.Blood advances · 2020Article
- The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.Blood · 2019Article
- Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.Clinical lymphoma, myeloma & leukemia · 2019Article
- Article
- Novel treatment approaches and future perspectives in follicular lymphoma.Therapeutic advances in hematology · 2019Review
- Sequencing of therapies in relapsed follicular lymphoma.Hematology. American Society of Hematology. Education Program · 2018Review
- Unmet needs in the first-line treatment of follicular lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Review
- Whither Radioimmunotherapy: To Be or Not To Be?Cancer research · 2017Review
- Recommendations for Clinical Trial Development in Follicular Lymphoma.Journal of the National Cancer Institute · 2017Review
- Targeted Radionuclide Therapy of Human Tumors.International journal of molecular sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
purposeThere is currently no consensus on optimal frontline therapy for patients with follicular lymphoma. We analyzed a phase III randomized intergroup trial comparing six cycles of CHOP-R (cyclophosphamide-Adriamycin-vincristine-prednisone (Oncovin)-rituximab) with six cycles of CHOP followed by iodine-131 tositumomab radioimmunotherapy (RIT) to assess whether any subsets benefited more from one treatment or the other, and to compare three prognostic models. EXPERIMENTAL
designWe conducted univariate and multivariate Cox regression analyses of 532 patients enrolled on this trial and compared the prognostic value of the FLIPI (follicular lymphoma international prognostic index), FLIPI2, and LDH + β2M (lactate dehydrogenase + β2-microglobulin) models.
resultsOutcomes were excellent, but not statistically different between the two study arms [5-year progression-free survival (PFS) of 60% with CHOP-R and 66% with CHOP-RIT (P = 0.11); 5-year overall survival (OS) of 92% with CHOP-R and 86% with CHOP-RIT (P = 0.08); overall response rate of 84% for both arms]. The only factor found to potentially predict the impact of treatment was serum β2M; among patients with normal β2M, CHOP-RIT patients had better PFS compared with CHOP-R patients, whereas among patients with high serum β2M, PFS by arm was similar (interaction P value = 0.02).
conclusionsAll three prognostic models (FLIPI, FLIPI2, and LDH + β2M) predicted both PFS and OS well, though the LDH + β2M model is easiest to apply and identified an especially poor risk subset. In an exploratory analysis using the latter model, there was a statistically significant trend suggesting that low-risk patients had superior observed PFS if treated with CHOP-RIT, whereas high-risk patients had a better PFS with CHOP-R.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.